Precision Medicine in Action: Multi-Tracer PET/CT Uncovers Tumor Heterogeneity and a Synchronous Malignancy

Precision oncology leverages molecular profiling to tailor cancer treatment, with nuclear medicine playing an increasingly central role, particularly in elderly patients, where noninvasive approaches are preferable. We present a case of a 76-year-old male with metastatic prostate carcinoma (Gleason score: 5 + 5 = 10) exhibiting neuroendocrine differentiation. Imaging with multiple positron emission tomography (PET) tracers- ⁶⁸ Ga-PSMA, ¹⁸ F-FDG, ⁶⁸ Ga-DOTATATE, and ⁶⁸ Ga-FAPI-revealed significant tumor heterogeneity. Tumor heterogeneity is multifactorial, influenced not only by genetic changes but also by epigenetic, microenvironmental, and therapeutic pressures. While ⁶⁸ Ga-PSMA PET/computed tomography (CT) showed variable expression in osteosclerotic lesions, ¹⁸ F-FDG PET/CT detected metabolic activity, and ⁶⁸ Ga-DOTATATE PET/CT confirmed low somatostatin receptor expression. Despite ¹⁷⁷ Lu-PSMA radioligand therapy, the disease progressed with rising prostate-specific antigen levels. Subsequent gastrointestinal symptoms led to the diagnosis of sigmoid colon adenocarcinoma, confirmed by ⁶⁸ Ga-FAPI PET/CT. This case exemplifies the critical role of nuclear imaging in characterizing tumor biology, guiding therapeutic strategies, and reducing reliance on invasive procedures. The integration of multi-tracer PET imaging enabled a nuanced understanding of tumor evolution, reinforcing nuclear medicine's importance in precision oncology and the management of complex, heterogeneous malignancies.